LU88795I2 - Mycophenolate mofetil ou un sel pharmaceutiquement acceptable de celui-ci - Google Patents

Mycophenolate mofetil ou un sel pharmaceutiquement acceptable de celui-ci

Info

Publication number
LU88795I2
LU88795I2 LU88795C LU88795C LU88795I2 LU 88795 I2 LU88795 I2 LU 88795I2 LU 88795 C LU88795 C LU 88795C LU 88795 C LU88795 C LU 88795C LU 88795 I2 LU88795 I2 LU 88795I2
Authority
LU
Luxembourg
Prior art keywords
pharmaceutically acceptable
agents
acceptable salt
mycophenolate mofetil
chem
Prior art date
Application number
LU88795C
Other languages
English (en)
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21733252&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU88795(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of LU88795I2 publication Critical patent/LU88795I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
LU88795C 1987-01-30 1987-12-15 Mycophenolate mofetil ou un sel pharmaceutiquement acceptable de celui-ci LU88795I2 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/008,717 US4753935A (en) 1987-01-30 1987-01-30 Morpholinoethylesters of mycophenolic acid and pharmaceutical compositions

Publications (1)

Publication Number Publication Date
LU88795I2 true LU88795I2 (fr) 1996-11-05

Family

ID=21733252

Family Applications (1)

Application Number Title Priority Date Filing Date
LU88795C LU88795I2 (fr) 1987-01-30 1987-12-15 Mycophenolate mofetil ou un sel pharmaceutiquement acceptable de celui-ci

Country Status (26)

Country Link
US (7) US4753935A (fr)
EP (1) EP0281713B1 (fr)
JP (1) JPS63188672A (fr)
KR (1) KR940003758B1 (fr)
AT (1) ATE68180T1 (fr)
AU (1) AU599728B2 (fr)
CA (1) CA1333285C (fr)
DE (2) DE3773660D1 (fr)
DK (1) DK166675B1 (fr)
ES (1) ES2038190T3 (fr)
FI (1) FI85141C (fr)
GE (1) GEP20094816B (fr)
GR (1) GR3002866T3 (fr)
HK (1) HK125893A (fr)
HU (2) HU201927B (fr)
IE (1) IE60750B1 (fr)
IL (1) IL84833A (fr)
LU (1) LU88795I2 (fr)
LV (1) LV5748B4 (fr)
MX (1) MX9203163A (fr)
NL (1) NL960019I2 (fr)
NO (2) NO171680C (fr)
NZ (1) NZ222922A (fr)
PH (1) PH23819A (fr)
PT (1) PT86343B (fr)
ZA (1) ZA879414B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177072A (en) * 1987-01-30 1993-01-05 Syntex (U.S.A.) Inc. Treatment of autoimmune inflammatory, and psoriatic diseases with heterocyclic aminoalkyl esters of mycophenolic acid and derivatives
DE69033342T2 (de) * 1989-02-23 2000-05-11 Univ North Carolina Etoposidanaloge
US5219851A (en) * 1991-03-05 1993-06-15 Warner-Lambert Company Tetrahydroisoquinoline-type renin inhibiting peptides
US5247083A (en) * 1992-07-10 1993-09-21 Syntex (U.S.A.) Inc. Direct esterification of mycophenolic acid
WO1994012184A1 (fr) * 1992-11-24 1994-06-09 Syntex (U.S.A.) Inc. Utilisation d'acide mycophenolique, de mofetile de mycophenolate ou d'un derive de ceux-ci pour inhiber la stenose
US5455045A (en) * 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
CA2165794A1 (fr) * 1993-06-25 1995-01-05 Brian Daunter Agent therapeutique
JP3411038B2 (ja) * 1993-09-15 2003-05-26 シンテックス（ユー・エス・エイ）・インコーポレイテッド ミコフェノール酸モフェチルの結晶質無水物およびその静注用製剤
PT721335E (pt) * 1993-10-01 2005-11-30 Roche Palo Alto Llc Suspensoes orais em altas doses de micofenolato de mofetil
US5444072A (en) * 1994-02-18 1995-08-22 Syntex (U.S.A.) Inc. 6-substituted mycophenolic acid and derivatives
US5525602A (en) * 1994-02-18 1996-06-11 Syntex (U.S.A.) Inc. Method of using 4-amino 6-substituted mycophenolic acid and derivatives
US5493030A (en) * 1994-02-18 1996-02-20 Syntex (U.S.A.) Inc. 5-substituted derivatives of mycophenolic acid
US5512568A (en) * 1994-02-18 1996-04-30 Syntex (U.S.A.) Inc. Method of using 4-amino derivatives of 5-substituted mycophenolic acid
US5380879A (en) * 1994-02-18 1995-01-10 Syntex (U.S.A.) Inc. Derivatives of mycophenolic acid
US6225073B1 (en) * 1994-07-07 2001-05-01 Dade Behring Marburg Gmbh Immunoassay for mycophenolic acid
ID18663A (id) 1996-04-12 1998-04-30 Novartis Ag Komposisi farmasi berlapis enterik
US6596747B2 (en) 1998-10-29 2003-07-22 Bristol-Myers Squibb Company Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
US6420403B1 (en) 1998-10-29 2002-07-16 Edwin J. Iwanowicz Inhibitors of IMPDH enzyme
WO2000025780A1 (fr) 1998-10-29 2000-05-11 Bristol-Myers Squibb Company Composes derives d'un noyau amine inhibiteurs de l'enzyme impdh
EP1127054A4 (fr) * 1998-10-29 2006-11-02 Bristol Myers Squibb Co Nouveaux inhibiteurs de l'enzyme impdh
IN188985B (fr) 1998-12-09 2002-11-30 Biocon Ltd
US6514979B1 (en) 1999-03-03 2003-02-04 University Of Maryland Biotechnology Institute Synergistic combinations of guanosine analog reverse transcriptase inhibitors and inosine monophosphate dehydrogenese inhibitors and uses therefor
US6107052A (en) * 1999-06-09 2000-08-22 Roche Diagnostics Corporation Enzymatic measurement of mycophenolic acid
CA2407370A1 (fr) * 2000-04-24 2001-11-01 Bristol-Myers Squibb Company Heterocycles utiles en tant qu'inhibiteurs de l'enzyme impdh
US6471980B2 (en) 2000-12-22 2002-10-29 Avantec Vascular Corporation Intravascular delivery of mycophenolic acid
US7179791B2 (en) * 2001-01-11 2007-02-20 Duke University Inhibiting GS-FDH to modulate NO bioactivity
GB0124953D0 (en) * 2001-10-17 2001-12-05 Novartis Ag Organic Compounds
TW200301698A (en) * 2001-12-21 2003-07-16 Bristol Myers Squibb Co Acridone inhibitors of IMPDH enzyme
EP2266590A3 (fr) 2002-02-22 2011-04-20 Shire LLC Système d'administration de substances actives et méthodes de protection et d'administration de substances actives
WO2004012746A2 (fr) * 2002-08-02 2004-02-12 The Regents Of The University Of California Nouvelles utilisations d'inhibiteurs de l'inosine monophosphate deshydrogenase
TWI221414B (en) * 2003-02-21 2004-10-01 Chunghwa Chemical Synthesis & Method of making mycophenolate mofetil using transesterification
GB0307553D0 (en) * 2003-04-01 2003-05-07 Novartis Ag Organic compounds
WO2004089946A1 (fr) * 2003-04-07 2004-10-21 Biocon Limited Synthese de mycophenolate-mofetil par irradiation par micro-ondes
ES2327639T3 (es) * 2003-05-14 2009-11-02 Dsm Ip Assets B.V. Uso de derivados de ftalida para el tratamiento y prevecion de diabetes mellitus.
US20050187170A1 (en) * 2003-06-16 2005-08-25 Biocryst Pharmaceuticals, Inc. Enhancing the efficiency of RNA polymerase inhibitors by using inosine monophosphate dehydrogenase inhibitors
ES2308226T3 (es) * 2003-09-11 2008-12-01 Sandoz Ag Proceso para la produccion de micofenolato mofetil.
CN100518733C (zh) * 2003-09-23 2009-07-29 帝斯曼知识产权资产管理有限公司 用于治疗和预防糖尿病的组合物
WO2005033089A1 (fr) * 2003-10-07 2005-04-14 Biocon Limited Sel d'acide 6-(1, 3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoique avec du diamide de n, n-dimethyl-imidodicarbonimidique
US7683188B2 (en) * 2004-04-26 2010-03-23 TEVA Gyógyszergyár Zártkōrūen Mūkōdō Részvénytársaság Process for preparation of mycophenolic acid and ester derivatives thereof
US20050250773A1 (en) * 2004-04-27 2005-11-10 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
EP1768662A2 (fr) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US7439373B2 (en) * 2004-07-20 2008-10-21 TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság Crystalline mycophenolate sodium
CA2577169A1 (fr) * 2004-08-16 2006-02-23 The University Of Queensland Agents de modulation du metabolisme et utilisations associees
AU2006207789B2 (en) * 2005-01-20 2012-11-22 Apotex Fermentation Inc. An improved process for the preparation of mycophenolate mofetil
US20060235070A1 (en) * 2005-02-08 2006-10-19 Hayden Michael R Compositions and methods for treating vascular, autoimmune, and inflammatory diseases
WO2006086498A2 (fr) * 2005-02-08 2006-08-17 Aspreva Pharmaceuticals Sa Traitement de maladies vasculaires, auto-immunes et inflammatoires, a l'aide de faibles doses d'inhibiteurs de l'impdh
US20080281111A1 (en) * 2005-04-26 2008-11-13 Sandor Molnar Process for preparation of mycophenolate mofetil and other esters of mycophenolic acid
CN100402516C (zh) * 2005-10-18 2008-07-16 深圳市东阳光实业发展有限公司 一种霉酚酸莫啡酯的制备方法
WO2007093346A1 (fr) * 2006-02-13 2007-08-23 Novartis Ag Doses élevées d'acide mycophénolique (mpa)
WO2008003637A2 (fr) * 2006-07-05 2008-01-10 Dsm Ip Assets B.V. Isolation et utilisation de sels aminés d'acide mycophénolique
WO2008033466A2 (fr) * 2006-09-14 2008-03-20 Combinatorx (Singapore) Pre. Ltd. Compositions et procédés pour le traitement de maladies virales
US20080188653A1 (en) 2007-02-04 2008-08-07 Formosa Laboratories, Inc. Process for Preparation of Mycophenolate Mofetil
CN100484930C (zh) * 2007-03-16 2009-05-06 重庆大新药业股份有限公司 一种吗替麦考酚酯的制备方法
WO2009000834A1 (fr) * 2007-06-27 2008-12-31 Dsm Ip Assets B.V. Procédé de purification de mycophénolate mofétil
WO2009010503A1 (fr) * 2007-07-18 2009-01-22 Dsm Ip Assets B.V. Recyclage d'acide mycophénolique dans un procédé de préparation de mycophénolate mofétil
US20090076000A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched mycophenolate mofetil
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
WO2009084008A1 (fr) * 2007-12-28 2009-07-09 Cadila Healthcare Limited Procédé de préparation de mycophénolate mofétil
KR100975520B1 (ko) * 2008-02-01 2010-08-12 종근당바이오 주식회사 마이코페놀레이트 모페틸의 개선된 제조방법
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010004435A2 (fr) * 2008-07-09 2010-01-14 Aspreva International Ltd. Formulations pour traiter des affections oculaires
EA019295B1 (ru) 2008-12-23 2014-02-28 Джилид Фармассет, Ллс. Соединения пуриновых нуклеозидов и способ их получения
US8551973B2 (en) * 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
EP2376088B1 (fr) 2008-12-23 2017-02-22 Gilead Pharmasset LLC Phosphoramidates de nucléosides de type 2-amino-purine 6-O-substituée
FI124873B (fi) 2009-10-06 2015-02-27 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
FI20096026L (fi) 2009-10-06 2011-04-07 Maricap Oy Menetelmä ja laitteisto pneumaattisessa materiaalinsiirtojärjestelmässä
JP2013527145A (ja) 2010-03-31 2013-06-27 ギリード・ファーマセット・エルエルシー リン含有活性化剤の立体選択的合成
GB201100786D0 (en) 2011-01-18 2011-03-02 Ems Sa Pharmaceutical compositions of immunosuppressants
CN102952105A (zh) * 2011-08-26 2013-03-06 中国科学院上海药物研究所 一类霉酚酸衍生物、其制备方法和用途
WO2013041205A1 (fr) 2011-09-19 2013-03-28 Pyxirion Pharma Gmbh Nouveaux concepts thérapeutiques pour le traitement de maladies vasculaires
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
HUE040044T2 (hu) 2013-03-14 2019-02-28 Alkermes Pharma Ireland Ltd Fumarátok prodrugjai, és azok alkalmazása különbözõ betegségek kezelésében
WO2015013422A1 (fr) * 2013-07-23 2015-01-29 University Of Tennessee Research Foundation Composés immunodépresseurs et agents thérapeutiques
RU2672872C2 (ru) * 2014-01-10 2018-11-20 Фуджифилм Корпорэйшн Способ и устройство для прогнозирования эффективной дозы или восприимчивости к 5-гидрокси-1н-имидазол-4-карбоксамиду, способ определения количества ксантозинмонофосфата, а также средство и способ для лечения миелодиспластического синдрома
US9604922B2 (en) 2014-02-24 2017-03-28 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
US10603299B2 (en) 2016-06-02 2020-03-31 Steven Baranowitz Prevention and treatment of viral infections
CA3026241A1 (fr) 2016-06-02 2017-12-07 Steven Baranowitz Prevention et traitement d'infections virales
US12011429B2 (en) 2016-06-02 2024-06-18 Steven Baranowitz Prevention and treatment of viral infections
US11918684B2 (en) 2017-03-13 2024-03-05 Liqmeds Worldwide Limited Pharmaceutical composition of oral suspension of immunosuppressive agents
US10835489B2 (en) * 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
CN110526885A (zh) * 2019-08-20 2019-12-03 上海英诺富成生物科技有限公司 麦考酚酸的前体药物及其制备方法
CN112121173B (zh) * 2020-08-22 2022-05-06 浙江大学 脂肪酸修饰的免疫抑制剂mmf及fk506纳米制剂及其制备方法和应用
CA3212370A1 (fr) 2021-03-03 2022-09-09 Sana Biotechnology, Inc. Therapies immunosuppressives destinees a etre utilisees avec des therapies cellulaires a base de cardiomyocytes, et methodes et compositions associees

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1157100A (en) * 1966-09-27 1969-07-02 Ici Ltd Pharmaceutical Compositions
GB1173942A (en) * 1967-06-06 1969-12-10 Bellon Labor Sa Roger New 2,3-Dihydro-1,4-Benzoxazines
GB1261060A (en) * 1969-09-09 1972-01-19 Ici Ltd Phthalen-1-one derivatives
US3825571A (en) * 1971-07-31 1974-07-23 Chugai Pharmaceutical Co Ltd Mycophenolic acid derivatives
JPS5542995B2 (fr) * 1972-02-24 1980-11-04
JPS563353B2 (fr) * 1972-03-02 1981-01-24
JPS5529994B2 (fr) * 1972-03-02 1980-08-07
US3868454A (en) * 1972-08-14 1975-02-25 Lilly Co Eli Psoriasis treatment with mycophenolic acid derivatives
US3777020A (en) * 1972-08-14 1973-12-04 Lilly Co Eli Psoriasis treatment with mycophenolic acid
US3880995A (en) * 1973-05-14 1975-04-29 Lilly Co Eli Treatment of arthritis with mycophenolic acid and derivatives
US3903071A (en) * 1973-05-22 1975-09-02 Lilly Co Eli Mycophenolic acid derivatives
US3905894A (en) * 1973-10-02 1975-09-16 Murskauskone Oy Apparatus for wet fine screening
JPS5724380A (en) * 1980-07-22 1982-02-08 Chugai Pharmaceut Co Ltd Preparation of mycophenolic acid derivative
JPS57183776A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
JPS57183777A (en) * 1981-05-01 1982-11-12 Ajinomoto Co Inc Preparation of mycophenolic acid derivative
IT1150194B (it) * 1982-02-23 1986-12-10 Chiesi Farma Spa Formulazioni farmaceutiche ad attivita'antiinfiammatoria, analgesica,antipiretica e gastroprotettiva

Also Published As

Publication number Publication date
NO875240L (no) 1988-08-01
NO171680C (no) 1993-04-21
FI85141C (fi) 1992-03-10
MX9203163A (es) 1992-07-31
FI85141B (fi) 1991-11-29
PH23819A (en) 1989-11-23
US4786637A (en) 1988-11-22
DK658787A (da) 1988-07-31
HUT47567A (en) 1989-03-28
FI875502A0 (fi) 1987-12-15
HK125893A (en) 1993-11-19
GEP20094816B (en) 2009-11-10
AU599728B2 (en) 1990-07-26
HU210350A9 (en) 1995-03-28
NO1997007I1 (no) 1997-07-01
NO171680B (no) 1993-01-11
IE60750B1 (en) 1994-08-10
PT86343A (en) 1988-01-01
US4992467A (en) 1991-02-12
EP0281713A1 (fr) 1988-09-14
ATE68180T1 (de) 1991-10-15
LV5748B4 (lv) 1997-02-20
NL960019I2 (nl) 1997-06-02
JPH0571591B2 (fr) 1993-10-07
ZA879414B (en) 1989-08-30
EP0281713B1 (fr) 1991-10-09
IL84833A (en) 1992-03-29
US4952579A (en) 1990-08-28
NO875240D0 (no) 1987-12-15
PT86343B (pt) 1991-02-08
IL84833A0 (en) 1988-06-30
FI875502A (fi) 1988-07-31
US4753935A (en) 1988-06-28
ES2038190T3 (es) 1993-07-16
US4948793A (en) 1990-08-14
NZ222922A (en) 1990-09-26
AU8254087A (en) 1988-08-04
HU201927B (en) 1991-01-28
DK658787D0 (da) 1987-12-15
IE873397L (en) 1988-07-30
US4808592A (en) 1989-02-28
DE3773660D1 (de) 1991-11-14
US4868153A (en) 1989-09-19
KR880009016A (ko) 1988-09-13
LV5748A4 (lv) 1996-10-20
DE19675020I2 (de) 2002-11-07
CA1333285C (fr) 1994-11-29
DK166675B1 (da) 1993-06-28
NL960019I1 (nl) 1996-10-01
GR3002866T3 (en) 1993-01-25
JPS63188672A (ja) 1988-08-04
KR940003758B1 (ko) 1994-04-30

Similar Documents

Publication Publication Date Title
LU88795I2 (fr) Mycophenolate mofetil ou un sel pharmaceutiquement acceptable de celui-ci
FI852974A0 (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
FI881816A (fi) Nya bicykliska foereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska blandningar.
FI922592A0 (fi) (arylalkylpiperidin-4-yl)metyl)-2a,3, 4,5-tetra-hydro-1(2h)-acetnaftylen-1-oner och motsvarande foereningar, foerfarande foer deras framstaellning och deras anvaendning som laekemedel.
FI92707C (fi) Menetelmä uusien terapeuttisesti käyttökelpoisten estramustiiniestereiden valmistamiseksi
EP0181592A3 (en) Use of spergualin derivatives for the preparation of medicaments having immunosuppressive activity
PT87005A (pt) Process for preparing n-phenethylaminoalkyl-benzamide anti-arrhythmic agents
NZ222015A (en) 7-(meta-substituted phenylglycine)-1-carba-1-dethiacephalsporins and pharmaceutical compositions
ATE100449T1 (de) 1,3-dioxolan-benzoesaeure und derivate davon.